News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biogen Idec, Inc. (Massachusetts) (BIIB): It's Unlikely Patient Death Was Caused by New MS Drug



7/23/2013 7:20:33 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

For a brief moment, there was significant investor anxiety that the ‘holy mother’ of all drug launches might burst like a balloon. A report that the new Tecfidera multiple sclerosis pill was possibly linked to a patient death sent shares downward amid speculation about whether the Biogen Idec drug may have a side effect problem that could thwart blockbuster sales estimates. But by the time the markets closed, the drugmaker had worked feverishly to dispel such concerns.

Help employers find you! Check out all the jobs and post your resume.

Read at Forbes
Read at Reuters
Read at Boston Globe
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES